Search our Database of Scientific Publications and Authors

I’m looking for a

    834 results match your criteria Buruli Ulcer

    1 OF 17

    Molecular Characterization of Mycolactone Producing Mycobacteria from Aquatic Environments in Buruli Ulcer Non-Endemic Areas in Côte d'Ivoire.
    Int J Environ Res Public Health 2017 Feb 11;14(2). Epub 2017 Feb 11.
    Department of Environment and Health, Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS), Adiopodoumé, 01 BP 1303, Abidjan 01, Côte d'Ivoire.
    Non-tuberculous mycobacteria (NTM), particularly mycolactone producing mycobacteria (MPM), are bacteria found in aquatic environments causing skin diseases in humans like Buruli ulcer (BU). Although the causative agent for BU, Mycobacterium ulcerans has been identified and associated with slow-moving water bodies, the real transmission route is still unknown. This study aimed to characterize MPMs from environmental aquatic samples collected in a BU non-endemic community, Adiopodoumé, in Côte d'Ivoire. Read More

    Design, synthesis, and cytotoxicity of stabilized mycolactone analogs.
    Bioorg Med Chem Lett 2017 Jan 17. Epub 2017 Jan 17.
    Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138, USA. Electronic address:
    On exposure to visible light, mycolactone A/B, the causative toxin of Buruli ulcer, rearranges to a mixture of four photo-mycolactones apparently via a rare photochemically-induced [4πs+2πa] cycloaddition. In order to prevent the rearrangement, two C6'-C7' dihydromycolactone analogs 6'α-15 and 6'β-15 were designed and synthesized. 6'α-15 and 6'β-15 were shown to be stable under not only photochemical, but also acidic and basic conditions. Read More

    Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.
    Pan Afr Med J 2016 1;25(Suppl 1):13. Epub 2016 Oct 1.
    Ghana Field Epidemiology and Laboratory Training programme, School of Public Health, University of Ghana.
    Introduction: Buruli ulcer (BU) is an infectious skin disease, caused by Mycobacterium ulcerans, endemic in more than 30 countries worldwide especially Africa. Brong-Ahafo Region implemented WHO recommended daily treatment with streptomycin and rifampicin for eight weeks (SR8). Yet limited assessment of therapy exists. Read More

    Multiple introductions and recent spread of the emerging human pathogen Mycobacterium ulcerans across Africa.
    Genome Biol Evol 2017 Jan 30. Epub 2017 Jan 30.
    Department of Biomedical Sciences, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
    Buruli ulcer (BU) is an insidious neglected tropical disease. Cases are reported around the world but the rural regions of West and Central Africa are most affected. How BU is transmitted and spreads has remained a mystery, even though the causative agent, Mycobacterium ulcerans, has been known for more than 70 years. Read More

    Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection.
    Int J Antimicrob Agents 2017 Jan 9. Epub 2017 Jan 9.
    Aix-Marseille Université, INSERM, CNRS, IRD, URMITE, Marseille, France. Electronic address:
    Mycobacterium ulcerans is responsible for Buruli ulcer, characterised by extensive, disabling ulcers. Standard treatment combining rifampicin and streptomycin exposes patients to toxicity and daily painful injections. In this study, the in vitro susceptibilities of 3 M. Read More

    High-Throughput Carbon Substrate Profiling of Mycobacterium ulcerans Suggests Potential Environmental Reservoirs.
    PLoS Negl Trop Dis 2017 Jan 17;11(1):e0005303. Epub 2017 Jan 17.
    Aix Marseille Univ, INSERM, CNRS, IRD, URMITE, Marseille, France.
    Background: Mycobacterium ulcerans is a close derivative of Mycobacterium marinum and the agent of Buruli ulcer in some tropical countries. Epidemiological and environmental studies pointed towards stagnant water ecosystems as potential sources of M. ulcerans, yet the ultimate reservoirs remain elusive. Read More

    Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    JBI Database System Rev Implement Rep 2017 Jan;15(1):119-139
    1The Cameroon Centre for Evidence Based Health Care: a Joanna Briggs Institute Centre of Excellence, Yaounde, Cameroon, Africa 2Centre for Behavioral and Social Research, Yaounde, Cameroon, Africa 3Centre for Evidence Based Initiatives in Health Care: a Joanna Briggs Institute Centre of Excellence, University of Wollongong, Wollongong, New South Wales, Australia 4St George Hospital, Sydney, New South Wales, Australia.
    Background: Buruli ulcer (BU) disease is a chronic ulcerative skin disease caused by Mycobacterium ulcerans, which can lead to extensive destruction of the skin, soft tissues and occasionally of bones. Although several antibiotics have demonstrated bactericidal activity against M. ulcerans in vitro, no consensus on their clinical efficacy against M. Read More

    Phytotherapy against buruli ulcer in the Health District of Yamoussoukro (Cote d'Ivoire) : Identification, description, and symbolic functions of the plants and recipes used.
    Med Sante Trop 2016 Nov;26(4):408-413
    Centre suisse de recherches sentifiques en Côte d'Ivoire, 01 BP 1303 Abidjan 01, Côte d'Ivoire.
    This study aims to describe the plants and recipes proposed by traditional healers against Buruli ulcer in Côte d'Ivoire and to analyze their symbolic aspects. Buruli ulcer is an increasingly serious health problem in Côte d'Ivoire. The ivorian state through the National Buruli Ulcer Control Programme and its partners, has developed various actions to fight that disease. Read More

    Susceptibility Profiles of Mycobacterium ulcerans Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana.
    Int J Microbiol 2016 14;2016:8304524. Epub 2016 Dec 14.
    Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
    Background. Drug resistance is a major challenge in antibiotic chemotherapy. Assessing resistance profiles of pathogens constitutes an essential surveillance tool in the epidemiology and control of infectious diseases, including Buruli ulcer (BU) disease. Read More

    Epidemiology of Mansonella perstans in the middle belt of Ghana.
    Parasit Vectors 2017 Jan 7;10(1):15. Epub 2017 Jan 7.
    Department of Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
    Background: Mansonellosis was first reported in Ghana by Awadzi in the 1990s. Co-infections of Mansonella perstans have also been reported in a small cohort of patients with Buruli ulcer and their contacts. However, no study has assessed the exact prevalence of the disease in a larger study population. Read More

    Evaluating decontamination protocols for the isolation of Mycobacterium ulcerans from swabs.
    BMC Microbiol 2017 Jan 5;17(1). Epub 2017 Jan 5.
    Swiss Tropical Institute, Basel, Switzerland.
    Background: Mycobacterium ulcerans (M. ulcerans) is the causative agent of Buruli Ulcer (BU) disease. In order to inhibit the growth of the microbial contaminants during culture of M. Read More

    Antimycobacterial potency and cytotoxicity study of three medicinal plants.
    Int J Mycobacteriol 2016 Dec 27;5 Suppl 1:S206-S207. Epub 2016 Oct 27.
    Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, Accra, Ghana.
    Objective/background: Mycobacterial infections including tuberculosis, leprosy, and buruli ulcer are among the most prevalent, debilitating, and deadly tropical diseases, especially in Sub-Saharan Africa. The development of drug resistance to the currently available drugs and the poor compliance emphasize the need for new chemotherapeutic agents. This study was designed to evaluate the in vitro activity of Cleistopholis patens, Annona reticulata, and Greenwayodendron suaveolens against Mycobacterium smegmatis. Read More

    Antimycobacterial ingredients from plants used in traditional medicine to treat Buruli ulcer.
    Int J Mycobacteriol 2016 Dec 29;5 Suppl 1:S204-S205. Epub 2016 Nov 29.
    Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, Accra, Ghana; Department of Pharmacology and Toxicology, School of Pharmacy, University of Ghana, Accra, Ghana.
    Aim And Objectives: Buruli ulcer (BU) is a neglected tropical disease caused by a mycobacteria, Mycobacterium ulcerans. The WHO recommended Rifampicin-Streptomycin combination side effects and poor compliance, leaves rural populations with no choice than to patronise indigenous remedies. This study is aimed at validating medicinal plants used in traditional medicine to treat BU by investigating the in vitro efficacy and safety as well as their composition in active molecules. Read More

    Antimycobacterial activity of medicinal plants against the causative agent of buruli ulcer: Mycobacterium ulcerans.
    Int J Mycobacteriol 2016 Dec 23;5 Suppl 1:S105. Epub 2016 Nov 23.
    Antimicrobial and Biocontrol Agents Unit, Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
    Objective/background: Buruli ulcer, known as necrotizing skin disease caused by Mycobacterium ulcerans, has emerged as the most prevalent mycobacteriosis after leprosy and tuberculosis. Accordingly, it has been classified by the World Health Organization as a neglected disease with high significance in tropical areas, including Cameroon. So far, the control of the disease relies mainly on the rifampin-streptomycin combination. Read More

    Characteristics and epidemiological profile of Buruli ulcer in the district of Tiassalé, south Côte d'Ivoire.
    Acta Trop 2016 Dec 27. Epub 2016 Dec 27.
    Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouët-Boigny, 01 BP V 34, Abidjan 01, Côte d'Ivoire.
    Buruli ulcer (BU) is a cutaneous infectious disease caused by Mycobacterium ulcerans. It is the third most common mycobacterial disease in the world in the immunocompetent patient and second in Côte d'Ivoire after tuberculosis. This study aimed to assess the characteristics and epidemiological profile of BU in the district of Tiassalé, an important focus of the disease in south Côte d'Ivoire, in order to better direct actions for prevention and control. Read More

    Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
    PLoS Negl Trop Dis 2016 Dec 29;10(12):e0005261. Epub 2016 Dec 29.
    University of Groningen, University Medical Center Groningen, Department of Internal Medicine/Infectious Diseases, Groningen, The Netherlands.
    Background: Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical disease frequently leading to permanent disabilities. The ulcers are treated with rifampicin and streptomycin, wound care and, if necessary surgical intervention. Professionals have exclusively shaped the research agenda concerning management and control, while patients' perspective on priorities and preferences have not explicitly been explored or addressed. Read More

    Secondary bacterial isolates from previously untreated Buruli ulcer lesions and their antibiotic susceptibility patterns in Southern Nigeria.
    Rev Soc Bras Med Trop 2016 Nov-Dec;49(6):746-751
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria.
    Introduction:: Mycolactones, secreted by Mycobacterium ulcerans, were previously believed to prevent super infection in Buruli ulcer lesions. However, little is known about secondary bacterial infections in these lesions. This study evaluated contaminating bacterial flora and their antibiotic susceptibility patterns in cases of previously untreated Buruli ulcer disease from three states in Southern Nigeria. Read More

    Financial burden of health care for Buruli ulcer patients in Nigeria: the patients' perspective.
    Int Health 2017 Jan 15;9(1):36-43. Epub 2016 Dec 15.
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria
    Background: The economic burden of Buruli ulcer for patients has not been well-documented. This study assessed the costs of Buruli ulcer care to patients from the onset of illness to diagnosis and to the end of treatment.

    Methods: This was a cross-sectional cost of illness study conducted among patients with Buruli ulcer in four States in Nigeria between July and September 2015. Read More

    Deforestation-driven food-web collapse linked to emerging tropical infectious disease, Mycobacterium ulcerans.
    Sci Adv 2016 Dec 7;2(12):e1600387. Epub 2016 Dec 7.
    Faculty of Science and Technology, Department of Life and Environmental Sciences, Bournemouth University, Dorset BH12 5BB, UK.; Institut de Recherche pour le Développement, UMR MIVEGEC IRD-CNRS-Université de Montpellier, Centre IRD de Montpellier, BP 64501, Montpellier, France.; Institut de Recherche pour le Développement, UMR BOREA IRD-MNHN-Université Pierre et Marie Curie, Muséum National d'Histoire Naturelle, 47 rue Cuvier, 75231 Paris cedex 5, France.
    Generalist microorganisms are the agents of many emerging infectious diseases (EIDs), but their natural life cycles are difficult to predict due to the multiplicity of potential hosts and environmental reservoirs. Among 250 known human EIDs, many have been traced to tropical rain forests and specifically freshwater aquatic systems, which act as an interface between microbe-rich sediments or substrates and terrestrial habitats. Along with the rapid urbanization of developing countries, population encroachment, deforestation, and land-use modifications are expected to increase the risk of EID outbreaks. Read More

    Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
    PLoS Negl Trop Dis 2016 Dec 12;10(12):e0005229. Epub 2016 Dec 12.
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
    Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells, recombinant MU DNA, or MU protein prime-boosts, have shown promise by conferring transient protection to mice against the pathology of MU challenge. Recently, we have shown that a recombinant BCG vaccine expressing MU-Ag85A (BCG MU-Ag85A) displayed the highest level of protection to date, by significantly extending the survival time of MU challenged mice compared to BCG vaccination alone. Read More

    Mycobacterium ulcerans toxin, mycolactone may enhance host-seeking and oviposition behaviour by Aedes aegypti (L.) (Diptera: Culicidae).
    Environ Microbiol 2016 Dec 1. Epub 2016 Dec 1.
    Texas A&M University, College Station, TX, USA.
    The ecological functions of many toxins continue to remain unknown for those produced by environmental pathogens. Mycobacterium ulcerans, the causative agent of the neglected tropical disease, Buruli ulcer, produces a cytotoxic macrolide, mycolactone, whose function(s) in the environment remains elusive. Through a series of dual-choice behaviour assays, they show that mycolactone may be an interkingdom cue for the yellow fever mosquito, Aedes aegypti, seeking blood-meals as well as oviposition sites. Read More

    Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates.
    PLoS One 2016 28;11(11):e0167059. Epub 2016 Nov 28.
    Swiss Tropical and Public Health Institute, Basel, Switzerland.
    Buruli Ulcer is a neglected tropical disease leading to extensive disabilities and morbidity in West Africa. In this paper we sought to characterize various strains of Mycobacterium ulcerans (M.ulcerans) with different origins and laboratory passage records while refining a mouse model for Buruli ulcer. Read More

    Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients.
    Am J Trop Med Hyg 2016 Nov 12;95(5):1011-1015. Epub 2016 Sep 12.
    Department of Internal Medicine/Infectious Diseases Groningen, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
    Buruli ulcer (BU) is one of the 17 neglected tropical diseases for which the World Health Organization has adopted resolutions to improve treatment. BU was previously described as a relatively painless condition; however, recent research has indicated that some patients experience substantial pain. The objective of this study was to explore patients' experiences of pain and their expectations for its treatment. Read More

    Mycobacterium ulcerans in the Daintree 2009-2015 and the mini-epidemic of 2011.
    ANZ J Surg 2016 Nov 1. Epub 2016 Nov 1.
    Department of Surgery, Cairns Hospital, Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia.
    Background: Mycobacterium ulcerans infection (Buruli ulcer) is the third most common mycobacterial disease in humans, with presentations ranging from self-limiting skin nodules and ulcers to aggressive infiltrative infections with extensive oedema, fat and skin necrosis. The two foci in Australia are in Victoria and Far North Queensland. We present the 2009-2015 case series for the Queensland focus with special reference to the 2011 spike of 64 cases. Read More

    Diagnosis delay and duration of hospitalisation of patients with Buruli ulcer in Nigeria.
    Trans R Soc Trop Med Hyg 2016 Sep 23;110(9):502-509. Epub 2016 Oct 23.
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria
    Background: Delayed diagnosis of Buruli ulcer can worsen clinical presentation of the disease, prolong duration of management, and impose avoidable additional costs on patients and health providers. We investigated the profile, delays in diagnosis, duration of hospitalisation, and associated factors among patients with Buruli ulcer in Nigeria.

    Methods: This was a prospective cohort study of patients with Buruli ulcer who were identified from a community-based survey. Read More

    RNA Aptamer That Specifically Binds to Mycolactone and Serves as a Diagnostic Tool for Diagnosis of Buruli Ulcer.
    PLoS Negl Trop Dis 2016 Oct 24;10(10):e0004950. Epub 2016 Oct 24.
    Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
    Background: Buruli ulcer (BU) is a subcutaneous skin disease listed among the neglected tropical diseases by the World Health Organization (WHO). Early case detection and management is very important to reduce morbidity and the accompanied characteristic disfiguring nature of BU. Since diagnosis based on clinical evidence can lead to misdiagnosis, microbiological confirmation is essential to reduce abuse of drugs; since the anti-mycobacterial drugs are also used for TB treatment. Read More

    Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    PLoS Negl Trop Dis 2016 Oct 18;10(10):e0005066. Epub 2016 Oct 18.
    Sorbonne Universités, UPMC Univ Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bactériologie), F-75013, Paris, France.
    Background: The treatment of Buruli ulcer (BU) that is caused by Mycobacterium ulcerans, is currently based on a daily administration of rifampin and streptomycin (RIF-STR). A fully oral intermittent regimen would greatly simplify its treatment on the field.

    Methodology/principal Findings: The objective of this study was to assess the bactericidal and sterilizing activities of intermittent oral regimens in a murine model of established M. Read More

    The Burden of Leprosy in Cameroon: Fifteen Years into the Post-elimination Era.
    PLoS Negl Trop Dis 2016 Oct 12;10(10):e0005012. Epub 2016 Oct 12.
    Faculty of Medicine and Biomedical Sciences, The University of Yaounde 1, Yaounde, Cameroon.
    Background: Cameroon achieved the elimination target of leprosy in 2000, and has maintained this status ever since. However, a number of health districts in the country continue to report significant numbers of leprosy cases. The aim of this study was to assess the burden of leprosy in Cameroon from 2000 to 2014. Read More

    Complete Genome Sequence of Mycobacterium ulcerans subsp. shinshuense.
    Genome Announc 2016 Sep 29;4(5). Epub 2016 Sep 29.
    Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Higashi-Murayama, Tokyo, Japan
    Mycobacterium ulcerans subsp. shinshuense produces mycolactone and causes Buruli ulcer. Here, we report the complete sequence of its genome, which comprises a 5. Read More

    Maximizing microscopy as a diagnostic tool in peripheral health centres of BU endemic areas in Ghana.
    Int J Mycobacteriol 2015 Sep 6;4(3):184-90. Epub 2015 Jun 6.
    Swiss Tropical Institute, Basel, Switzerland.
    Background: Buruli ulcer (BU) disease, a skin condition caused by Mycobacterium ulcerans (M. ulcerans) is endemic in remote rural areas. Disease diagnosis on clinical basis alone can be misleading, requiring definitive diagnosis based on laboratory tests. Read More

    Detection of Mycobacterium ulcerans by real-time PCR with improved primers.
    Trop Med Health 2016 19;44(1):28. Epub 2016 Aug 19.
    Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641 Japan ; Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641 Japan.
    Background: Buruli ulcer is a severe skin disease caused by Mycobacterium ulcerans. Real-time PCR targeting the IS2404 sequence has been used as a reliable and rapid method for the diagnosis of Buruli ulcer and detection of M. ulcerans in the environment. Read More

    Possible healthcare-associated transmission as a cause of secondary infection and population structure of Staphylococcus aureus isolates from two wound treatment centres in Ghana.
    New Microbes New Infect 2016 Sep 12;13:92-101. Epub 2016 Jul 12.
    Noguchi Memorial Institute for Medical Research, Accra, Ghana.
    We have previously shown that secondary infections of Buruli ulcer wounds were frequently caused by Staphylococcus aureus. To gain understanding into possible routes of secondary infection, we characterized S. aureus isolates from patient lesions and surrounding environments across two Ghanaian health centres. Read More

    Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
    Trop Med Int Health 2016 Sep 26;21(9):1191-6. Epub 2016 Jul 26.
    Department of Internal Medicine, University Medical Center Groningen, Groningen University, Groningen, The Netherlands.
    Objectives: Buruli ulcer (BU) is a tropical skin disease caused by infection with Mycobacterium ulcerans, which is currently treated with 8 weeks of streptomycin and rifampicin. The evidence to treat BU for a duration of 8 weeks is limited; a recent retrospective study from Australia suggested that a shorter course of antimicrobial therapy might be equally effective. We studied the outcomes of BU in a cohort of Ghanaian patients who defaulted from treatment and as such received less than 8 weeks of antimicrobial therapy. Read More

    Cultural Understanding of Wounds, Buruli Ulcers and Their Management at the Obom Sub-district of the Ga South Municipality of the Greater Accra Region of Ghana.
    PLoS Negl Trop Dis 2016 Jul 20;10(7):e0004825. Epub 2016 Jul 20.
    Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
    Background: This study was conducted with the aim to understand some of the cultural belief systems in the management of wounds and patients practices that could contaminate wounds at the Obom sub-district of the Ga South Municipality of Ghana.

    Methods: This was an ethnographic study using in-depth interviews, Focus Group Discussions and participant observation techniques for data collection. Observations were done on Buruli ulcer patients to document how they integrate local and modern wound management practices in the day-to-day handling of their wounds. Read More

    Spatiotemporal Co-existence of Two Mycobacterium ulcerans Clonal Complexes in the Offin River Valley of Ghana.
    PLoS Negl Trop Dis 2016 Jul 19;10(7):e0004856. Epub 2016 Jul 19.
    Swiss Tropical and Public Health Institute, Basel, Switzerland.
    In recent years, comparative genome sequence analysis of African Mycobacterium ulcerans strains isolated from Buruli ulcer (BU) lesion specimen has revealed a very limited genetic diversity of closely related isolates and a striking association between genotype and geographical origin of the patients. Here, we compared whole genome sequences of five M. ulcerans strains isolated in 2004 or 2013 from BU lesions of four residents of the Offin river valley with 48 strains isolated between 2002 and 2005 from BU lesions of individuals residing in the Densu river valley of Ghana. Read More

    Clinical and Laboratory Diagnosis of Buruli Ulcer Disease: A Systematic Review.
    Can J Infect Dis Med Microbiol 2016 20;2016:5310718. Epub 2016 Jun 20.
    Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana; Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, Ghana.
    Background. Buruli ulcer (BU) is a necrotizing cutaneous infection caused by Mycobacterium ulcerans. Early diagnosis is crucial to prevent morbid effects and misuse of drugs. Read More

    Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management.
    Curr Pharm Des 2016 Jun 30. Epub 2016 Jun 30.
    Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Portugal.
    Infectious diseases in the skin represent a major group of pathologies that contribute annually for significant health economic expenses. According to WHO, Buruli Ulcer (BU) and Cutaneous Leishmaniasis (CL) are two neglected tropical diseases for which therapy remains inadequate. Topical delivery of therapeutics constitutes an advantageous alternative to treat infected skin lesions as it allows a direct treatment of affected areas avoiding unwanted systemic effects and reducing the drug dosage. Read More

    Steps Toward Creating A Therapeutic Community for Inpatients Suffering from Chronic Ulcers: Lessons from Allada Buruli Ulcer Treatment Hospital in Benin.
    PLoS Negl Trop Dis 2016 Jul 1;10(7):e0004602. Epub 2016 Jul 1.
    School of Anthropology, University of Arizona, Tucson, Arizona, United States of America.
    Background: Reducing social distance between hospital staff and patients and establishing clear lines of communication is a major challenge when providing in-patient care for people afflicted by Buruli ulcer (BU) and chronic ulcers. Research on hospitals as therapeutic communities is virtually non-existent in Africa and is currently being called for by medical anthropologists working in the field of health service and policy planning. This paper describes a pioneering attempt to establish a therapeutic community for patients suffering from BU and other chronic ulcers requiring long term hospital care in Benin. Read More

    Functional Diversity as a New Framework for Understanding the Ecology of an Emerging Generalist Pathogen.
    Ecohealth 2016 Sep 29;13(3):570-581. Epub 2016 Jun 29.
    Bournemouth University, School of Applied Sciences, Dorset, BH12 5BB, UK.
    Emerging infectious disease outbreaks are increasingly suspected to be a consequence of human pressures exerted on natural ecosystems. Previously, host taxonomic communities have been used as indicators of infectious disease emergence, and the loss of their diversity has been implicated as a driver of increased presence. The mechanistic details in how such pathogen-host systems function, however, may not always be explained by taxonomic variation or loss. Read More

    Mycolactone-mediated neurite degeneration and functional effects in cultured human and rat DRG neurons: Mechanisms underlying hypoalgesia in Buruli ulcer.
    Mol Pain 2016 20;12. Epub 2016 Jun 20.
    Department of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
    Background: Mycolactone is a polyketide toxin secreted by the mycobacterium Mycobacterium ulcerans, responsible for the extensive hypoalgesic skin lesions characteristic of patients with Buruli ulcer. A recent pre-clinical study proposed that mycolactone may produce analgesia via activation of the angiotensin II type 2 receptor (AT2R). In contrast, AT2R antagonist EMA401 has shown analgesic efficacy in animal models and clinical trials for neuropathic pain. Read More

    Snapshot fecal survey of domestic animals in rural Ghana for Mycobacterium ulcerans.
    PeerJ 2016 1;4:e2065. Epub 2016 Jun 1.
    Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity , Melbourne , Australia.
    Identifying the source reservoirs of Mycobacterium ulcerans is key to understanding the mode of transmission of this pathogen and controlling the spread of Buruli ulcer (BU). In Australia, the native possum can harbor M. ulcerans in its gastrointestinal tract and shed high concentrations of the bacteria in its feces. Read More

    Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis.
    PLoS Negl Trop Dis 2016 Jun 2;10(6):e0004767. Epub 2016 Jun 2.
    Swiss Tropical and Public Health Institute, Basel, Switzerland.
    Background: Current laboratory diagnosis of Buruli ulcer (BU) is based on microscopic detection of acid fast bacilli, quantitative real-time PCR (qPCR), histopathology or cultivation. Insertion sequence (IS) 2404 qPCR, the most sensitive method, is usually only available at reference laboratories. The only currently available point-of-care test, microscopic detection of acid fast bacilli (AFB), has limited sensitivity and specificity. Read More

    A Community Based Study on the Mode of Transmission, Prevention and Treatment of Buruli Ulcers in Southwest Cameroon: Knowledge, Attitude and Practices.
    PLoS One 2016 26;11(5):e0156463. Epub 2016 May 26.
    Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
    Background: Buruli ulcer (BU) is a neglected tropical disease affecting the skin, tissues and in some cases the bones, caused by the environmental pathogen Mycobacterium ulcerans (M. ulcerans). Its mode of transmission is still elusive. Read More

    Isolation of Nontuberculous Mycobacteria from the Environment of Ghanian Communities Where Buruli Ulcer Is Endemic.
    Appl Environ Microbiol 2016 Jul 30;82(14):4320-9. Epub 2016 Jun 30.
    Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
    Unlabelled: This study aimed to isolate nontuberculous mycobacterial species from environmental samples obtained from some selected communities in Ghana. To optimize decontamination, spiked environmental samples were used to evaluate four decontamination solutions and supplemented media, after which the best decontamination solution and media were used for the actual analysis. The isolates obtained were identified on the basis of specific genetic sequences, including heat shock protein 65, IS2404, IS2606, rpoB, and the ketoreductase gene, as needed. Read More

    Landscape Fragmentation as a Risk Factor for Buruli Ulcer Disease in Ghana.
    Am J Trop Med Hyg 2016 Jul 16;95(1):63-9. Epub 2016 May 16.
    Department of Geography, The Pennsylvania State University, University Park, Pennsylvania.
    Land cover and its change have been linked to Buruli ulcer (BU), a rapidly emerging tropical disease. However, it is unknown whether landscape structure affects the disease prevalence. To examine the association between landscape pattern and BU presence, we obtained land cover information for 20 villages in southwestern Ghana from high resolution satellite images, and analyzed the landscape pattern surrounding each village. Read More

    The Application of Modern Dressings to Buruli Ulcers: Results from a Pilot Implementation Project in Ghana.
    Am J Trop Med Hyg 2016 Jul 9;95(1):60-2. Epub 2016 May 9.
    Infectious Diseases Unit, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
    Buruli ulcer (BU) is a tropical, infectious skin disease. The resulting ulcer can take a long time to heal, and a high standard of wound care is essential. Currently, the only dressing used for BU wound care is gauze, and its removal causes pain and bleeding. Read More

    Molecular Species Delimitation and Morphology of Aquatic and Sub-Aquatic Bugs (Heteroptera) in Cameroon.
    PLoS One 2016 5;11(5):e0154905. Epub 2016 May 5.
    UMR EGCE (Évolution, Génomes, Comportement, Écologie), CNRS IRD- Université Paris-Sud, Université Paris-Saclay, Gif-sur-Yvette Cedex, Gif-sur-Yvette, France.
    Aquatic and semi-aquatic bugs (Heteroptera) represent a remarkable diversity and a resurging interest has been given to documenting at the species level these insects inhabiting Cameroon in Central Africa due to their potential implication in the transmission of the bacterium Mycobacterium ulcerans, the causal agent of Buruli ulcer, an emerging human disease. A survey was carried out over two years in Cameroon. Morphological analyses were done in two steps. Read More

    Genetic Variation in Autophagy-Related Genes Influences the Risk and Phenotype of Buruli Ulcer.
    PLoS Negl Trop Dis 2016 Apr 29;10(4):e0004671. Epub 2016 Apr 29.
    Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
    Introduction: Buruli ulcer (BU) is a severe necrotizing human skin disease caused by Mycobacterium ulcerans. Clinically, presentation is a sum of these diverse pathogenic hits subjected to critical immune-regulatory mechanisms. Among them, autophagy has been demonstrated as a cellular process of critical importance. Read More

    1 OF 17